Piper Jaffray Reiterates Overweight on Eidos Therapeutics, Raises Price Target to $75

Piper Jaffray reiterates Eidos Therapeutics (NASDAQ:EIDX) with a Overweight and raises the price target from $55 to $75.

Benzinga · 11/19/2019 14:24

Piper Jaffray reiterates Eidos Therapeutics (NASDAQ:EIDX) with a Overweight and raises the price target from $55 to $75.